A Multiple Oral Ascending Dose Study to Investigate the Safety, Pharmacokinetics and Catechol-O-methyltransferase (COMT) Inhibition Profiles of Opicapone in Healthy Male Subjects.

Trial Profile

A Multiple Oral Ascending Dose Study to Investigate the Safety, Pharmacokinetics and Catechol-O-methyltransferase (COMT) Inhibition Profiles of Opicapone in Healthy Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs Opicapone (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Bial
  • Most Recent Events

    • 25 Feb 2014 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT02071810).
    • 11 Sep 2012 Results presented at the 16th Congress of the European Federation of Neurological Societies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top